Moleculin reports 60% enrollment for first interim unblinding of Phase 3 AML trial

Moleculin Biotech, Inc.

60% of target 45 subjects for first interim unblinding of MIRACLE (R/R AML) trial have consented (as of Nov 4, 2025).
Completion of treatment for first 45 subjects expected Q1 2026; unblinding thereafter.
Blinded response activity tracking within expected range based on historical trial arm responses.
CEO notes strong recruitment momentum despite EU bed shortages.
Annamycin has FDA Fast Track and Orphan Drug designations for R/R AML; patent protection through 2040-2045.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.